320 related articles for article (PubMed ID: 33275709)
1. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
4. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
6. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
Patel K; Danilov AV; Pagel JM
Blood; 2019 Nov; 134(19):1573-1577. PubMed ID: 31554637
[TBL] [Abstract][Full Text] [Related]
7. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
Gadi D; Griffith A; Tyekucheva S; Wang Z; Rai V; Vartanov A; Thrash E; Fernandes SM; Lehmberg TZ; Lee B; Martindale SP; Machado JH; Odejide O; Armand P; Fisher DC; Arnason J; Davids MS; Lederer JA; Brown JR
Leukemia; 2022 Mar; 36(3):723-732. PubMed ID: 34743191
[TBL] [Abstract][Full Text] [Related]
8. Duvelisib for the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
[TBL] [Abstract][Full Text] [Related]
9. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
10. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
[TBL] [Abstract][Full Text] [Related]
11. B cell receptor inhibition as a target for CLL therapy.
Jeyakumar D; O'Brien S
Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
[TBL] [Abstract][Full Text] [Related]
12. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
[TBL] [Abstract][Full Text] [Related]
13. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Makita S; Ota S; Mishima Y; Usuki K; Ennishi D; Yanada M; Fukuhara N; Yamamoto R; Takamine A; Nohara G; Izutsu K
Int J Hematol; 2024 Feb; 119(2):156-163. PubMed ID: 38150138
[TBL] [Abstract][Full Text] [Related]
14. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
[TBL] [Abstract][Full Text] [Related]
15. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
16. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
O'Brien S; Patel M; Kahl BS; Horwitz SM; Foss FM; Porcu P; Jones J; Burger J; Jain N; Allen K; Faia K; Douglas M; Stern HM; Sweeney J; Kelly P; Kelly V; Flinn I
Am J Hematol; 2018 Nov; 93(11):1318-1326. PubMed ID: 30094870
[TBL] [Abstract][Full Text] [Related]
17. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Curigliano G; Shah RR
Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
[TBL] [Abstract][Full Text] [Related]
18. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Skånland SS; Brown JR
Haematologica; 2023 Jan; 108(1):9-21. PubMed ID: 35899388
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
20. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Flinn IW; Hillmen P; Montillo M; Nagy Z; Illés Á; Etienne G; Delgado J; Kuss BJ; Tam CS; Gasztonyi Z; Offner F; Lunin S; Bosch F; Davids MS; Lamanna N; Jaeger U; Ghia P; Cymbalista F; Portell CA; Skarbnik AP; Cashen AF; Weaver DT; Kelly VM; Turnbull B; Stilgenbauer S
Blood; 2018 Dec; 132(23):2446-2455. PubMed ID: 30287523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
